Live Biotherapeutic Products: Unique Quality, Manufacturing, And Nonclinical Considerations For Clinical Trial Entry
Source: Novotech
Live Biotherapeutics (LBPs) are no longer just a scientific curiosity, they are becoming one of the most promising frontiers in modern medicine.
By harnessing live microorganisms to restore or modulate human health, LBPs are opening new pathways for treating chronic and complex diseases with precision and minimal toxicity. From gastrointestinal and metabolic disorders to neurodegeneration and oncology, LBPs have the potential to fundamentally reshape how we approach drug development.
As interest in LBPs accelerates, Novotech’s recent white paper outlines the opportunities and early-stage challenges shaping this rapidly advancing therapeutic class.